#USA #New York #Fesarius #DermiSphere #Jefferson Life Sciences

Fesarius Therapeutics Closes Oversubscribed $20 Million Series A Funding

Fesarius Therapeutics, a pioneering medical technology company focused on advancing dermal repair solutions, recently announced that it has successfully completed an oversubscribed Series A funding round, raising a total of $20 million. The financing was led by Jefferson Life Sciences, with participation from well-known investors including Johnson & Johnson, NY Ventures, and the American Society of Plastic Surgeons (ASPS).

The funds will significantly support the company's flagship product, DermiSphere™, a groundbreaking hydrogel Dermal Regeneration Template (hDRT) that was cleared by the FDA in 2025 for various wound management applications. DermiSphere™ stands out in the market as the first of its kind, leveraging an innovative dual-density collagen microarchitecture designed to promote faster cellular infiltration and vascularization, which are crucial for effective wound healing.

A Major Milestone in Dermal Repair

With the $20 million in new funding, Fesarius Therapeutics is poised for substantial growth, expanding its reach across the U.S. hospital systems. The investment will allow the company to enhance its commercial infrastructure, including hiring additional representatives to strengthen market coverage. Furthermore, Fesarius aims to pursue Breakthrough Device Designation to open new reimbursement pathways and advance clinical trials for its innovative OneStep procedure. This procedure, which involves placing DermiSphere™ along with a skin graft in a single surgery, has the potential to greatly reduce patient recovery time and overall treatment costs by eliminating the need for two separate surgeries.

The U.S. market for dermal regeneration is valued at approximately $1.6 billion, yet it has experienced minimal innovation over the past three decades. DermiSphere™ addresses this gap by offering a novel approach that hastens the body's natural wound healing process, making a tangible difference for patients requiring skin grafts due to traumatic injuries or surgical interventions.

Expert Opinions on the Innovation

Laura Lande-Diner, Managing Partner at Jefferson Life Sciences, expressed excitement about supporting Fesarius's mission: "We are thrilled to back Fesarius in its efforts to transform deep wound care and improve patient outcomes for millions who require skin grafts. DermiSphere™ is already proving its worth to patients."

Jennifer Tegan, Managing Director at NY Ventures, highlighted New York's growing life sciences ecosystem, stating, "Companies like Fesarius exemplify the innovative landscape we strive to foster, offering advancements that significantly benefit patient health while creating valuable jobs in the state."

Michael Costelloe from ASPS Ventures noted that this investment marks a significant evolution for the organization, transitioning from advocacy to active collaboration in promoting member innovations. He emphasized their commitment to bringing forward technology that addresses critical patient needs.

Tom Roueche, President and CEO of Fesarius Therapeutics, reiterated the transformative potential of their technology, stating, "DermiSphere™ is pioneering a new era in dermal repair, fundamentally altering how wounds are treated. This funding will accelerate our programs and ensure broad patient access to the remarkable results we are achieving with DermiSphere™."

About Fesarius Therapeutics

Founded and headquartered in New York, Fesarius Therapeutics is on a mission to redefine dermal repair strategies. Its DermiSphere™ product, with its patented dual-density collagen structure, is not just a medical device; it represents a shift in the approach to complex wound healing. With ongoing commitments to expanding its clinical program and supporting label expansions, Fesarius Therapeutics is dedicated to shaping the future of wound care.

For further insights into their innovative technologies, visit Fesarius Therapeutics.